AAAAAA

   
Results: 1-7 |
Results: 7
Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis
Authors: Moreland, LW McCabe, DP Caldwell, JR Sack, M Weisman, M Henry, G Seely, JE Martin, SW Yee, CL Bendele, AM Frazier, JL Kohno, T Cosenza, ME Lyons, SA Dayer, JM Cohen, AM Edwards, CK
Citation: Lw. Moreland et al., Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis, J RHEUMATOL, 27(3), 2000, pp. 601-609
Pharmacologic actions of the second generation leukotriene B-4 receptor antagonist LY293111: in vivo pulmonary studies
Authors: Silbaugh, SA Stengel, PW Cockerham, SL Froelich, LL Bendele, AM Spaethe, SM Sofia, MJ Sawyer, JS Jackson, WT
Citation: Sa. Silbaugh et al., Pharmacologic actions of the second generation leukotriene B-4 receptor antagonist LY293111: in vivo pulmonary studies, N-S ARCH PH, 361(4), 2000, pp. 397-404
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis
Authors: Bendele, AM Chlipala, ES Scherrer, J Frazier, J Sennello, G Rich, WJ Edwards, CK
Citation: Am. Bendele et al., Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis, ARTH RHEUM, 43(12), 2000, pp. 2648-2659
Treatment of rheumatoid arthritis with PEGylated recombinant human solubletumour necrosis factor receptor type I: a clinical update
Authors: Davis, MW Feige, U Bendele, AM Martin, SW Edwards, CK
Citation: Mw. Davis et al., Treatment of rheumatoid arthritis with PEGylated recombinant human solubletumour necrosis factor receptor type I: a clinical update, ANN RHEUM D, 59, 2000, pp. 41-43
Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats
Authors: Bendele, AM McComb, J Gould, T Frazier, J Chlipala, ES Seely, J Kieft, G Wolf, J Edwards, CK
Citation: Am. Bendele et al., Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats, INFLAMM RES, 48(8), 1999, pp. 453-460
Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats
Authors: Bendele, AM McComb, J Gould, T Frazier, J Chlipala, E Seely, J Kieft, G Edwards, CK
Citation: Am. Bendele et al., Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats, CLIN EXP RH, 17(5), 1999, pp. 553-560
Regulatory decision strategy for entry of a novel biologic therapeutic with a clinically unmonitorable toxicity into clinical trials: Pre-IND meetings and a case example
Authors: Black, LE Bendele, AM Bendele, RA Zack, PM Hamilton, M
Citation: Le. Black et al., Regulatory decision strategy for entry of a novel biologic therapeutic with a clinically unmonitorable toxicity into clinical trials: Pre-IND meetings and a case example, TOX PATHOL, 27(1), 1999, pp. 22-26
Risultati: 1-7 |